The Woodlands, TX, Aug. 3, 2017 /Newswire-Newswire/ — Osteobiologic Solutions, Inc. a medical device development company specializing in orthobiologics, today announced the release of AmnioJel™, a premium addition to Osteobiologic Solutions’ amnion portfolio.
AmnioJel™ combines the benefits of the amnion layer and the amniotic fluid which have proven to provide enhanced wound healing, reduction of pain and inflammation and reduction of adhesions. The proprietary processing also preserves the tissues growth factors such as TGF-β1, bFGF, BMP-2, EGF, PDGF-AA, PDGF-BB, FGF, VEGF and IGF. All of these growth factors help initiate and nurture wound healing without potential drawbacks. When rehydrated AmnioJel™ forms into a putty like consistency that has good handling characteristics, as it is moldable, compressible and shapeable for insertion into any wound or void.
“AmnioJel™ underscores our commitment to offering surgeons the advanced regenerative solutions they need to support their patients’ healing,” said Robert Bundy, Osteobiologic Solutions’ President.
The addition of AmnioJel™ enhances the Osteobiologic Solutions regenerative portfolio which include OBS Demineralized Bone Matrix Putty, OBS Demineralized Bone, and ReVIVIFY™ amniotic membrane and fluid. This line expansion provides surgeons with another regenerative tool to meet a variety of needs for patients.